Sage Therapeutics Inc. (NASDAQ:SAGE)‘s stock had its “buy” rating reiterated by equities research analysts at Cowen and Company in a research report issued to clients and investors on Monday.

The analysts wrote, “SAGE presented posters with additional analysis of the ‘547 Ph1/2 data at the.””

Several other analysts have also issued reports on SAGE. Chardan Capital assumed coverage on shares of Sage Therapeutics in a research report on Tuesday, May 24th. They set a “sell” rating and a $18.00 price target on the stock. Canaccord Genuity reissued a “buy” rating on shares of Sage Therapeutics in a research report on Friday, May 27th. Leerink Swann reissued an “outperform” rating and issued a $66.00 price objective on shares of Sage Therapeutics in a research report on Tuesday, June 21st. HC Wainwright assumed coverage on shares of Sage Therapeutics in a research report on Thursday, June 23rd. They issued a “buy” rating and a $56.00 price objective on the stock. Finally, BMO Capital Markets assumed coverage on shares of Sage Therapeutics in a research report on Tuesday, June 28th. They issued an “outperform” rating and a $48.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $67.67.

Sage Therapeutics (NASDAQ:SAGE) traded up 2.66% during trading on Monday, reaching $45.08. The company’s stock had a trading volume of 469,504 shares. Sage Therapeutics has a 12-month low of $26.28 and a 12-month high of $62.64. The firm’s 50-day moving average price is $39.68 and its 200 day moving average price is $35.50. The company’s market capitalization is $1.45 billion.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($1.08) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.02) by $0.06. On average, analysts predict that Sage Therapeutics will post ($4.38) earnings per share for the current fiscal year.

In other Sage Therapeutics news, CFO Kimi Iguchi sold 2,500 shares of the stock in a transaction dated Wednesday, September 7th. The shares were sold at an average price of $40.93, for a total transaction of $102,325.00. Following the sale, the chief financial officer now directly owns 81,239 shares in the company, valued at $3,325,112.27. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Albert Robichaud sold 22,000 shares of the stock in a transaction dated Tuesday, July 12th. The stock was sold at an average price of $40.00, for a total transaction of $880,000.00. Following the sale, the insider now owns 140,222 shares in the company, valued at $5,608,880. The disclosure for this sale can be found here. Company insiders own 5.60% of the company’s stock.

A number of large investors have recently made changes to their positions in SAGE. Franklin Resources Inc. increased its stake in shares of Sage Therapeutics by 7.8% in the first quarter. Franklin Resources Inc. now owns 1,287,805 shares of the biopharmaceutical company’s stock worth $41,287,000 after buying an additional 93,474 shares during the last quarter. BlackRock Group LTD increased its stake in shares of Sage Therapeutics by 71.3% in the first quarter. BlackRock Group LTD now owns 6,908 shares of the biopharmaceutical company’s stock worth $222,000 after buying an additional 2,875 shares during the last quarter. Clarius Group LLC purchased a new stake in shares of Sage Therapeutics during the first quarter worth about $3,557,000. BlackRock Fund Advisors increased its stake in shares of Sage Therapeutics by 17.1% in the first quarter. BlackRock Fund Advisors now owns 787,546 shares of the biopharmaceutical company’s stock worth $25,249,000 after buying an additional 115,027 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of Sage Therapeutics by 6.2% in the first quarter. JPMorgan Chase & Co. now owns 1,025,990 shares of the biopharmaceutical company’s stock worth $32,893,000 after buying an additional 59,582 shares during the last quarter. Hedge funds and other institutional investors own 93.93% of the company’s stock.

About Sage Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. Its lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor.

5 Day Chart for NASDAQ:SAGE

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.